/주식/MEDP
MEDP

MEDP

USD

Medpace Holdings Inc. Common Stock

$301.565-0.055 (-0.018%)

실시간 가격

Healthcare
Diagnostics & Research
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$301.620

고가

$301.910

저가

$301.170

거래량

0.31M

기업 기본 정보

시가총액

8.7B

산업

Diagnostics & Research

국가

United States

거래 통계

평균 거래량

0.49M

거래소

NMS

통화

USD

52주 범위

저가 $250.05현재가 $301.565고가 $459.77

관련 뉴스

Analyst Upgrades

Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $300

Truist Securities analyst Jailendra Singh maintains Medpace Hldgs with a Hold and lowers the price target from $333 to $300.

더 보기
Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $300
Analyst Upgrades

Baird Maintains Neutral on Medpace Hldgs, Lowers Price Target to $313

Baird analyst Eric Coldwell maintains Medpace Hldgs with a Neutral and lowers the price target from $340 to $313.

더 보기
Baird Maintains Neutral on Medpace Hldgs, Lowers Price Target to $313
Analyst Upgrades

William Blair Downgrades Medpace Hldgs to Market Perform

William Blair analyst Max Smock downgrades Medpace Hldgs from Outperform to Market Perform.

더 보기
William Blair Downgrades Medpace Hldgs to Market Perform
BusinessWire

Medpace Holdings, Inc. Reports First Quarter 2025 Results

Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were

더 보기
Medpace Holdings, Inc. Reports First Quarter 2025 Results
Analyst Upgrades

TD Cowen Downgrades Medpace Hldgs to Hold, Lowers Price Target to $328

TD Cowen analyst Charles Rhyee downgrades Medpace Hldgs from Buy to Hold and lowers the price target from $370 to $328.

더 보기
TD Cowen Downgrades Medpace Hldgs to Hold, Lowers Price Target to $328
Analyst Upgrades

Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $333

Truist Securities analyst Jailendra Singh maintains Medpace Hldgs with a Hold and lowers the price target from $347 to $333.

Analyst Upgrades

Mizuho Maintains Outperform on Medpace Hldgs, Lowers Price Target to $355

Mizuho analyst Ann Hynes maintains Medpace Hldgs with a Outperform and lowers the price target from $400 to $355.